Bendamustine and Radiation Therapy in Treating Patients With Brain Metastases Caused by Solid Tumors

Inclusion Criteria: * Histologically confirmed cancer with 1 to 4 brain metastases imaged by MRI/CT scans not involving thalamus, basal ganglia or brain stem. * No cancer originating in central nervous system * Candidate for clinically indicated surgery to resect brain lesions. * Karnofsky score of at least 60 * At least 18 years of age * Life expectancy of more than two months Exclusion Criteria: * Evidence of leptomeningeal metastases. * Need immediate treatment to prevent neurological deterioration. * Prior brain radiotherapy or surgery for current brain metastases. * Radiosensitive primary tumors such as small cell lung cancer, germ cell tumors, lymphoma, leukemia or multiple myeloma. * Absolute neutrophil count (ANC)\<1500/mm3 or platelets \<50,000/mms. * Brain metastasis diameter greater than 5 cm. * Not pregnant or nursing * More than 3 weeks since prior chemotherapy. * No evidence of ischemia on EKG and/or reduced cardiac ejection fraction (i.e., \< 50%) on ECHO. * No known sensitivity or allergy to bendamustine hydrochloride or mannitol * No more than 3 prior cytotoxic chemotherapy regimens * No unresolved persistent toxicities for 4 weeks from prior chemotherapy or 6 weeks for nitrosoureas. * Calculated creatinine clearance \<40 ml/min.